Symbols / SCYX Stock $5.33 -5.50% SCYNEXIS, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
SCYX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. David Gonzalez Angulo M.D.
Exch · Country NCM · United States
Market Cap 52.93M
Enterprise Value 366.23M
Income -24.52M
Sales 20.34M
FCF (ttm) 2.65M
Book/sh 0.67
Cash/sh 0.75
Employees 18
Insider 10d —
IPO May 02, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.12
PEG —
P/S 2.60
P/B 8.00
P/C —
EV/EBITDA —
EV/Sales 18.00
Quick Ratio 3.73
Current Ratio 3.94
Debt/Eq 4.99
LT Debt/Eq —
EPS (ttm) -3.84
EPS next Y -2.52
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-05-11
ROA -20.96%
ROE -53.39%
ROIC —
Gross Margin 100.00%
Oper. Margin -119.95%
Profit Margin -120.51%
Shs Outstand 9.93M
Shs Float 57.60M
Insider Own —
Instit Own —
Short Float 2.92%
Short Ratio 5.90
Short Interest 284.22K
52W High 10.48
vs 52W High -49.14%
52W Low 4.52
vs 52W Low 17.92%
Beta —
Impl. Vol. 9.14%
Rel Volume 2.19
Avg Volume 73.55K
Volume 161.44K
Target (mean) $33.55
Tgt Median $32.00
Tgt Low $24.00
Tgt High $44.64
# Analysts 3
Recom Strong_buy
Prev Close $5.64
Price $5.33
Change -5.50%
About

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$33.55
Mean price target
2. Current target
$5.33
Latest analyst target
3. DCF / Fair value
$4.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.33
Low
$24.00
High
$44.64
Mean
$33.55

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-28 main Guggenheim Buy → Buy $3
2024-04-01 reit Cantor Fitzgerald — → Overweight —
2023-08-15 reit Cantor Fitzgerald Overweight → Overweight $15
2023-04-03 main Guggenheim — → Buy $9
2023-04-03 reit Ladenburg Thalmann — → Buy $15
2023-03-01 init Guggenheim — → Buy $8
2022-05-13 main HC Wainwright & Co. — → Buy $8
2022-03-31 main HC Wainwright & Co. — → Buy $14
2021-06-07 main Aegis Capital — → Buy $35
2021-04-12 main Aegis Capital — → Buy $40
2021-01-22 init Guggenheim — → Buy $25
2021-01-06 init Cantor Fitzgerald — → Overweight $30
2020-12-28 reit HC Wainwright & Co. — → Buy $20
2020-04-23 main Aegis Capital — → Buy $5
2018-10-16 main Maxim Group Buy → Buy $4
2018-06-27 init Maxim Group — → Buy $6
2018-05-24 init Ladenburg Thalmann — → Buy $9
2018-04-10 init Seaport Global — → Buy $4
2017-10-24 init Guggenheim — → Buy $6
2017-01-31 init Aegis Capital — → Buy $7
News
RSS: Latest SCYX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 ANGULO GONZALEZ DAVID Chief Executive Officer — 108,695 — —
2026-01-29 ANGULO GONZALEZ DAVID Chief Executive Officer — 391,333 — —
2026-01-29 SUKENICK SCOTT A. J.D. Officer — 129,833 — —
2026-01-29 MACLEOD IVOR Chief Financial Officer — 129,833 — —
2025-10-17 ANGULO GONZALEZ DAVID Chief Executive Officer — 32,500 $0.76 $24,700
2025-06-26 ANIDO ARMANDO Director — 23,000 — —
2025-06-26 HASTINGS DAVID C Director — 23,000 — —
2025-06-26 HANHAM ANN F Director — 23,000 — —
2025-06-26 MACDONALD GUY Director — 23,000 — —
2025-06-26 GILMAN STEVEN C Director — 23,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
20.60
+449.95%
3.75
-97.33%
140.14
+2652.72%
5.09
Operating Revenue
20.60
+449.95%
3.75
-97.33%
140.14
+2652.72%
5.09
Cost Of Revenue
—
0.00
-100.00%
15.62
+2387.90%
0.63
Reconciled Cost Of Revenue
—
0.00
-100.00%
15.62
+2387.90%
0.63
Gross Profit
—
3.75
-96.99%
124.52
+2689.98%
4.46
Operating Expense
36.67
-10.25%
40.86
-21.19%
51.85
-42.53%
90.22
Research And Development
22.28
-15.62%
26.41
-14.62%
30.93
+13.46%
27.26
Selling General And Administration
14.39
-0.44%
14.46
-30.89%
20.92
-66.77%
62.96
Total Expenses
36.67
-10.25%
40.86
-39.44%
67.47
-25.73%
90.85
Operating Income
-16.07
+56.69%
-37.12
-151.08%
72.67
+184.74%
-85.76
Total Operating Income As Reported
-16.07
+56.69%
-37.12
-151.08%
72.67
+184.74%
-85.76
EBITDA
-8.44
+58.46%
-20.31
-128.65%
70.89
+214.88%
-61.70
Normalized EBITDA
-14.21
+58.59%
-34.32
-146.24%
74.21
+186.98%
-85.32
Reconciled Depreciation
—
0.00
-100.00%
0.58
-4.29%
0.61
EBIT
-8.44
+58.46%
-20.31
-128.89%
70.31
+212.84%
-62.31
Total Unusual Items
5.77
-58.79%
14.01
+521.93%
-3.32
-114.06%
23.62
Total Unusual Items Excluding Goodwill
5.77
-58.79%
14.01
+521.93%
-3.32
-114.06%
23.62
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Pretax Income
-8.61
+59.27%
-21.14
-131.46%
67.18
+199.51%
-67.51
Net Non Operating Interest Income Expense
1.69
-2.59%
1.74
+180.05%
-2.17
+59.61%
-5.37
Interest Expense Non Operating
0.17
-79.11%
0.83
-73.55%
3.13
-39.78%
5.20
Net Interest Income
1.69
-2.59%
1.74
+180.05%
-2.17
+59.61%
-5.37
Interest Expense
0.17
-79.11%
0.83
-73.55%
3.13
-39.78%
5.20
Interest Income Non Operating
2.18
-49.27%
4.29
+8.52%
3.95
+179.43%
1.42
Interest Income
2.18
-49.27%
4.29
+8.52%
3.95
+179.43%
1.42
Other Income Expense
5.77
-59.47%
14.24
+529.01%
-3.32
-114.06%
23.62
Other Non Operating Income Expenses
—
0.23
—
0.00
Gain On Sale Of Security
5.77
-58.79%
14.01
+521.93%
-3.32
-114.06%
23.62
Tax Provision
0.00
-100.00%
0.15
+9.42%
0.14
+102.94%
-4.70
Tax Rate For Calcs
0.00
-100.00%
0.00
+20900.00%
0.00
-98.56%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
2.94
+88704.82%
-0.00
-100.20%
1.64
Net Income Including Noncontrolling Interests
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Net Income From Continuing Operation Net Minority Interest
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Net Income From Continuing And Discontinued Operation
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Net Income Continuous Operations
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Normalized Income
-14.38
+55.55%
-32.35
-145.99%
70.36
+182.99%
-84.78
Net Income Common Stockholders
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Diluted EPS
-0.17
+61.36%
-0.44
-131.65%
1.39
+194.56%
-1.47
Basic EPS
-0.17
+61.36%
-0.44
-131.43%
1.40
+195.24%
-1.47
Basic Average Shares
49.93
+2.93%
48.51
+1.38%
47.85
+12.29%
42.61
Diluted Average Shares
49.93
+2.93%
48.51
+0.25%
48.39
+13.56%
42.61
Diluted NI Availto Com Stockholders
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Other Taxes
—
—
—
—
Total Other Finance Cost
0.31
-81.92%
1.73
-42.35%
2.99
+88.42%
1.59
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
59.03
-34.88%
90.64
-29.41%
128.41
+46.24%
87.81
Current Assets
40.37
-44.07%
72.18
-29.31%
102.12
+29.16%
79.06
Cash Cash Equivalents And Short Term Investments
40.03
-32.49%
59.30
-20.25%
74.36
+1.17%
73.50
Cash And Cash Equivalents
21.26
+32.45%
16.05
-52.86%
34.05
-25.68%
45.81
Other Short Term Investments
18.77
-56.60%
43.25
+7.29%
40.31
+45.59%
27.69
Receivables
0.00
-100.00%
10.26
-52.98%
21.83
+938.84%
2.10
Accounts Receivable
—
—
0.00
-100.00%
2.10
Other Receivables
—
10.26
-52.98%
21.83
—
Inventory
—
—
0.00
-100.00%
0.90
Raw Materials
—
—
0.00
-100.00%
0.27
Work In Process
—
—
0.00
-100.00%
0.61
Finished Goods
—
—
0.00
-100.00%
0.02
Prepaid Assets
0.25
-74.11%
0.95
+47.98%
0.64
-73.70%
2.44
Restricted Cash
0.08
-81.61%
0.43
+14.47%
0.38
+590.91%
0.06
Other Current Assets
0.02
-98.62%
1.23
-74.85%
4.91
+7812.90%
0.06
Total Non Current Assets
18.65
+1.03%
18.46
-29.79%
26.30
+200.56%
8.75
Net PPE
1.76
-15.60%
2.09
-11.59%
2.36
-8.87%
2.59
Gross PPE
1.76
-15.60%
2.09
-11.59%
2.36
-8.87%
2.59
Accumulated Depreciation
—
—
—
—
Machinery Furniture Equipment
—
—
—
—
Other Properties
1.76
-15.60%
2.09
-11.59%
2.36
-8.87%
2.59
Goodwill And Other Intangible Assets
—
—
0.00
-100.00%
0.41
Investments And Advances
16.25
+2.53%
15.85
-32.84%
23.59
0.00
Non Current Deferred Assets
0.53
+27.82%
0.42
+138.29%
0.17
+139.73%
0.07
Other Non Current Assets
0.11
+0.00%
0.11
-33.13%
0.16
-97.13%
5.67
Total Liabilities Net Minority Interest
9.65
-72.86%
35.57
-35.86%
55.45
-34.44%
84.58
Current Liabilities
5.73
-76.21%
24.10
+47.82%
16.30
-7.46%
17.62
Payables And Accrued Expenses
3.51
-46.83%
6.60
-49.05%
12.95
+40.04%
9.25
Payables
2.23
-51.30%
4.57
-36.09%
7.15
+20.41%
5.94
Accounts Payable
2.23
-51.30%
4.57
-36.09%
7.15
+20.41%
5.94
Current Accrued Expenses
1.28
-36.75%
2.03
-65.02%
5.80
+75.21%
3.31
Pensionand Other Post Retirement Benefit Plans Current
1.51
-14.52%
1.76
+4.20%
1.69
-26.94%
2.32
Current Debt And Capital Lease Obligation
0.48
-96.57%
14.10
+4045.59%
0.34
+20.57%
0.28
Current Debt
—
13.69
—
—
Other Current Borrowings
—
13.69
—
—
Current Capital Lease Obligation
0.48
+18.67%
0.41
+19.71%
0.34
+20.57%
0.28
Current Deferred Liabilities
0.23
-85.69%
1.64
+38.10%
1.19
0.00
Current Deferred Revenue
0.23
-85.69%
1.64
+38.10%
1.19
0.00
Other Current Liabilities
—
—
0.13
-97.75%
5.77
Total Non Current Liabilities Net Minority Interest
3.92
-65.84%
11.47
-70.71%
39.15
-41.54%
66.96
Long Term Debt And Capital Lease Obligation
1.69
-22.21%
2.17
-85.24%
14.74
-69.49%
48.31
Long Term Debt
—
—
12.16
-73.21%
45.39
Long Term Capital Lease Obligation
1.69
-22.21%
2.17
-15.73%
2.58
-11.64%
2.92
Non Current Deferred Liabilities
0.00
-100.00%
1.29
-52.55%
2.73
0.00
Non Current Deferred Revenue
0.00
-100.00%
1.29
-52.55%
2.73
0.00
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
49.38
-10.35%
55.08
-24.51%
72.96
+2156.79%
3.23
Common Stock Equity
49.38
-10.35%
55.08
-24.51%
72.96
+2156.79%
3.23
Capital Stock
0.05
+12.20%
0.04
+2.50%
0.04
+11.11%
0.04
Common Stock
0.05
+12.20%
0.04
+2.50%
0.04
+11.11%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
43.54
+14.66%
37.97
+2.06%
37.21
+13.85%
32.68
Ordinary Shares Number
43.54
+14.66%
37.97
+2.06%
37.21
+13.85%
32.68
Additional Paid In Capital
434.47
+0.67%
431.57
+0.79%
428.17
+0.63%
425.49
Retained Earnings
-385.14
-2.29%
-376.54
-5.99%
-355.25
+15.88%
-422.29
Total Equity Gross Minority Interest
49.38
-10.35%
55.08
-24.51%
72.96
+2156.79%
3.23
Total Capitalization
49.38
-10.35%
55.08
-35.30%
85.12
+75.05%
48.63
Working Capital
34.64
-27.96%
48.08
-43.97%
85.81
+39.66%
61.44
Invested Capital
49.38
-28.20%
68.77
-19.21%
85.12
+75.05%
48.63
Total Debt
2.17
-86.63%
16.27
+7.89%
15.08
-68.97%
48.60
Capital Lease Obligations
2.17
-15.76%
2.58
-11.61%
2.92
-8.80%
3.20
Net Tangible Assets
49.38
-10.35%
55.08
-24.51%
72.96
+2482.73%
2.83
Tangible Book Value
49.38
-10.35%
55.08
-24.51%
72.96
+2482.73%
2.83
Derivative Product Liabilities
2.23
-72.18%
8.00
-63.11%
21.68
+16.28%
18.64
Held To Maturity Securities
16.25
+2.53%
15.85
-32.84%
23.59
0.00
Investmentin Financial Assets
16.25
+2.53%
15.85
-32.84%
23.59
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.28
+78.00%
-24.01
-139.91%
60.16
+175.31%
-79.88
Cash Flow From Continuing Operating Activities
-5.28
+78.00%
-24.01
-139.91%
60.16
+175.31%
-79.88
Net Income From Continuing Operations
-8.61
+59.56%
-21.29
-131.75%
67.04
+206.74%
-62.81
Depreciation Amortization Depletion
—
0.00
-100.00%
0.58
-4.29%
0.61
Depreciation And Amortization
—
0.00
-100.00%
0.58
-4.29%
0.61
Other Non Cash Items
0.64
-68.07%
2.00
-38.03%
3.22
+79.51%
1.80
Stock Based Compensation
2.85
-14.76%
3.35
+27.52%
2.62
-28.81%
3.69
Asset Impairment Charge
—
0.00
-100.00%
15.35
0.00
Operating Gains Losses
-5.77
+58.79%
-14.01
-521.93%
3.32
+114.06%
-23.62
Gain Loss On Investment Securities
-5.77
+58.79%
-14.01
-521.93%
3.32
+114.06%
-23.62
Change In Working Capital
6.08
-16.48%
7.28
+123.77%
-30.64
-4110.99%
0.76
Change In Receivables
10.26
-11.26%
11.56
+158.63%
-19.73
-1490.73%
-1.24
Changes In Account Receivables
—
0.00
-100.00%
2.10
+269.44%
-1.24
Change In Inventory
—
0.00
+100.00%
-8.85
-1929.59%
-0.44
Change In Prepaid Assets
2.17
-36.07%
3.39
+214.04%
-2.97
-281.60%
1.64
Change In Payables And Accrued Expense
-3.24
+49.05%
-6.35
-309.05%
3.04
+295.87%
-1.55
Change In Accrued Expense
-1.00
+72.93%
-3.70
-298.34%
1.87
+2765.71%
-0.07
Change In Payable
-2.23
+15.70%
-2.65
-326.11%
1.17
+179.14%
-1.48
Change In Account Payable
-2.23
+15.70%
-2.65
-326.11%
1.17
+179.14%
-1.48
Change In Other Working Capital
-2.70
-176.00%
-0.98
-125.00%
3.92
—
Change In Other Current Liabilities
-0.41
-20.06%
-0.34
+94.40%
-6.05
-357.03%
2.35
Investing Cash Flow
24.31
+295.22%
6.15
+117.63%
-34.88
-27.34%
-27.39
Cash Flow From Continuing Investing Activities
24.31
+295.22%
6.15
+117.63%
-34.88
-27.34%
-27.39
Net PPE Purchase And Sale
—
—
—
—
Purchase Of PPE
—
—
—
—
Capital Expenditure
—
—
—
-0.01
Net Investment Purchase And Sale
24.31
+295.22%
6.15
+117.63%
-34.88
-27.38%
-27.38
Purchase Of Investment
-18.90
+48.09%
-36.42
+57.40%
-85.48
-212.20%
-27.38
Sale Of Investment
43.21
+1.51%
42.57
-15.88%
50.60
0.00
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.01
Purchase Of Intangibles
—
—
0.00
+100.00%
-0.01
Financing Cash Flow
-14.17
-10094.24%
-0.14
+99.62%
-36.72
-175.55%
48.60
Cash Flow From Continuing Financing Activities
-14.17
-10094.24%
-0.14
+99.62%
-36.72
-175.55%
48.60
Net Issuance Payments Of Debt
-14.00
0.00
+100.00%
-36.65
-832.92%
5.00
Issuance Of Debt
—
—
0.00
-100.00%
5.00
Repayment Of Debt
-14.00
0.00
+100.00%
-36.65
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
5.00
Long Term Debt Payments
-14.00
0.00
+100.00%
-36.65
0.00
Net Long Term Debt Issuance
-14.00
0.00
+100.00%
-36.65
-832.92%
5.00
Net Common Stock Issuance
0.01
0.00
-100.00%
0.02
-99.96%
47.25
Proceeds From Stock Option Exercised
0.05
-8.93%
0.06
+33.33%
0.04
+133.33%
0.02
Net Other Financing Charges
-0.23
-15.90%
-0.20
-44.44%
-0.14
+96.32%
-3.66
Changes In Cash
4.85
+126.96%
-18.00
-57.34%
-11.44
+80.50%
-58.67
Beginning Cash Position
16.59
-52.03%
34.59
-24.85%
46.03
-56.04%
104.70
End Cash Position
21.45
+29.24%
16.59
-52.03%
34.59
-24.85%
46.03
Free Cash Flow
-5.28
+78.00%
-24.01
-139.91%
60.16
+175.30%
-79.89
Interest Paid Supplemental Data
0.42
-50.00%
0.84
-74.14%
3.25
-37.42%
5.19
Amortization Of Securities
-0.47
+64.63%
-1.34
+0.00%
-1.34
-333.66%
-0.31
Common Stock Issuance
0.01
0.00
-100.00%
0.02
-99.96%
47.25
Issuance Of Capital Stock
0.01
0.00
-100.00%
0.02
-99.96%
47.25
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category